Spots Global Cancer Trial Database for Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Official Title: An Open-label, Multicenter, Phase 2 Basket Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Study ID: NCT04809012

Conditions

Solid Tumor

Refractory Tumor

Relapsed Solid Tumor

Interventions

STI-3031

Study Description

Brief Summary: This study evaluates the efficacy of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected solid tumors.

Detailed Description: This is an open-label, multicenter, Phase 2 basket study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of STI-3031, an anti-PD-L1 antibody, in patients with selected RRSTs. All participants will receive STI-3031 20 mg/kg every 2 weeks (Q2W) via IV infusion over approximately 60 minutes.